Neumora Therapeutics Inc. [NMRA] stock is trading at $15.51, up 0.71%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NMRA shares have gain 5.08% over the last week, with a monthly amount glided 31.11%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Neumora Therapeutics Inc. [NASDAQ: NMRA] stock has seen the most recent analyst activity on October 01, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $30. Previously, Needham started tracking the stock with Buy rating on July 22, 2024, and set its price target to $23. On July 08, 2024, Mizuho initiated with a Outperform rating and assigned a price target of $20 on the stock. Deutsche Bank started tracking the stock assigning a Hold rating and suggested a price target of $13 on December 12, 2023. William Blair initiated its recommendation with a Outperform and recommended $26 as its price target on October 10, 2023. Stifel started tracking with a Buy rating for this stock on October 10, 2023, and assigned it a price target of $26. In a note dated October 10, 2023, RBC Capital Mkts initiated an Outperform rating and provided a target price of $24 on this stock.
Neumora Therapeutics Inc. [NMRA] stock has fluctuated between $8.33 and $21.00 over the past year. Currently, Wall Street analysts expect the stock to reach $24.5 within the next 12 months. Neumora Therapeutics Inc. [NASDAQ: NMRA] shares were valued at $15.51 at the most recent close of the market. An investor can expect a potential return of 57.96% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.68, Equity is -0.61 and Total Capital is -0.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.21 points at the first support level, and at 14.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.86, and for the 2nd resistance point, it is at 16.21.
Ratios To Look Out For
For context, Neumora Therapeutics Inc.’s Current Ratio is 17.22. As well, the Quick Ratio is 17.22, while the Cash Ratio is 6.52.
Transactions by insiders
Recent insider trading involved Lenz Robert A., Head of R&D, that happened on Oct 10 ’24 when 8260.0 shares were sold. Head of R&D, Lenz Robert A. completed a deal on Oct 09 ’24 to sell 5563.0 shares. Meanwhile, Officer Lenz Robert A. bought 8260.0 shares on Oct 10 ’24.
